Lumos held an investor briefing outlining the transformational US$317 million distribution agreement with PHASE Scientific.
Company News
Video | Investor Briefing | PHASE Scientific Agreement
16 Jul 2025
Keep reading
More news & media.
A few more pieces along the same thread. See the full index for everything.
COMPANY NEWS
1 min read
REPLAY | FebriDx US Launch Update
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
LD
Lumos Diagnostics Communications
Written with AI assistance
COMPANY NEWS
2 min read
100+ Locations and Growing: A Milestone for FebriDx® Adoption
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
LD
Lumos Diagnostics Communications
Written with AI assistance
COMPANY NEWS
1 min read
Lumos Achieves 250 Patient Milestone in FebriDx® Paediatric Study
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...
LD
Lumos Diagnostics Communications
Written with AI assistance